Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials

被引：0

作者：

Takayuki Hamano

Yusuke Yamaguchi

Kashia Goto

Shaka Martin

Alina Jiletcovici

Frank Dellanna

Tadao Akizawa

Jonathan Barratt

机构：

[1] Nagoya City University Graduate School of Medical Sciences,Department of Nephrology

[2] Astellas Pharma Global Development Inc.,undefined

[3] Astellas Pharma,undefined

[4] Inc.,undefined

[5] MVZ DaVita Rhein-Ruhr GmbH,undefined

[6] Showa University School of Medicine,undefined

[7] University of Leicester,undefined

来源：

Advances in Therapy | 2024年 / 41卷

关键词：

Anemia; Chronic kidney disease; Roxadustat; Thromboembolism;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1553 / 1575

页数：22

共 28 条

[21] Percutaneous coronary intervention versus coronary artery bypass graft surgery in dialysis-dependent patients: A pooled meta-analysis of reconstructed time-to-event data
Tasoudis, Panagiotis T.
Varvoglis, Dimitrios N.
Tzoumas, Andreas
Doulamis, Ilias P.
Tzani, Aspasia
Sa, Michel P.
Kampaktsis, Polydoros N.
Gallo, Michele
JOURNAL OF CARDIAC SURGERY, 2022, 37 (10) : 3365 - 3373
[22] Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non–dialysis-dependent stage 3–5 chronic kidney disease from the Salford Kidney Study
Ana Filipa Alexandre
Matthias Stoelzel
Amit Kiran
Alberto Garcia-Hernandez
Antonia Morga
Philip A. Kalra
Journal of Nephrology, 2023, 36 : 1639 - 1649
[23] Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials
Palmer, Jeanne
Mazerolle, Flora
Liu, Tom
M'Hari, Manal
Regnault, Antoine
Zhang, Shiyuan
Cardellino, Anna
Wang, Zhaohui
Strouse, Bryan
Sahni, Jasmine
LeBlanc, Thomas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S409 - S410
[24] Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials
Amin, Alpesh N.
Menoyo, Jose
Singh, Bhupinder
Kim, Christopher S.
BMC NEPHROLOGY, 2019, 20 (01)
[25] Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
Koenig, Wolfgang
Conde, Lorena Garcia
Landmesser, Ulf
Leiter, Lawrence A.
Ray, Kausik K.
Schwartz, Gregory G.
Wright, R. Scott
Han, Jackie
Raal, Frederick J.
CARDIOVASCULAR DRUGS AND THERAPY, 2024, 38 (03) : 493 - 503
[26] Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non-dialysis-dependent stage 3-5 chronic kidney disease from the Salford Kidney Study
Alexandre, Ana Filipa
Stoelzel, Matthias
Kiran, Amit
Garcia-Hernandez, Alberto
Morga, Antonia
Kalra, Philip A. A.
JOURNAL OF NEPHROLOGY, 2023, 36 (06) : 1639 - 1649
[27] Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials
Diana L. Shuster
Rajeev M. Menon
Bifeng Ding
Amit Khatri
Hong Li
Eric Cohen
Melissa Jewett
Daniel E. Cohen
Jiuhong Zha
European Journal of Clinical Pharmacology, 2019, 75 : 207 - 216
[28] Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials
Shuster, Diana L.
Menon, Rajeev M.
Ding, Bifeng
Khatri, Amit
Li, Hong
Cohen, Eric
Jewett, Melissa
Cohen, Daniel E.
Zha, Jiuhong
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (02) : 207 - 216

← 1 2 3 →